Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Alimera Sciences Inc
ALIMAlimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia. Address: 6310 Town Square, Alpharetta, GA, United States, 30005
Analytics
Precio Objetivo de WallStreet
5.67 USDRelación P/E
5.2667Rentabilidad por dividendo
–Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave ALIM
Análisis de dividendos ALIM
Aumento del dividendo durante 5 años
–Crecimiento continuo
–Ratio de pago medio en 5 años
–Tendencia del payout ALIM
Valoración de la acción ALIM
Finanzas ALIM
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |